Download PDF
Thromb Haemost 2011; 106(05): 753-754
DOI: 10.1160/TH11-08-0580
Invited Editorial Focus
Schattauer GmbH

Stroke prevention in non-valvular atrial fibrillation: Can warfarin do better?

Stavros Apostolakis
1   University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
,
Gregory Y. H. Lip
1   University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
› Author Affiliations
Further Information

Publication History

Received: 18 August 2011

Accepted:23 August 2011

Publication Date:
23 November 2017 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Camm AJ, Kirchhof P, Lip GY. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
    CrossrefPubMedGoogle Scholar
  • 2 Keogh C, Wallace E, Dillon C. et al. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost 2011; 106: 528-538.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe?. Thromb Haemost 2010; 104: 45-48.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Olesen JB, Lip GY, Lindhardsen J. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost. 2011; 106: 739-751.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Apostolakis S, Shantsila E, Lip GY. et al. Contra: “Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation”. Thromb Haemost 2009; 102: 914-915.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Odén A, Fahlén M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res 2006; 117: 493-499.
    CrossrefPubMedGoogle Scholar
  • 7 Lane DA, Lip GY. Anticoagulation intensity for elderly atrial fibrillation patients: should we use a conventional INR target (2.0 to 3.0) or a lower range?. Thromb Haemost 2010; 103: 254-256.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Rosendaal FR, Cannegieter SC, van der Meer FJ. et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematology 2004; 126: 557-564.
    CrossrefPubMedGoogle Scholar
  • 10 Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost. 2010; 104: 49-60.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?. Thromb Haemost 2011; 105: 574-578.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Gallagher A, Setakis E, Plumb JM. et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-977.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Connolly SJ, Pogue J, Eikelboom J. et al. ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
    CrossrefPubMedGoogle Scholar
  • 14 Reynolds MW, Fahrbach K, Hauch O. et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004; 126: 1938-1945.
    CrossrefPubMedGoogle Scholar
  • 15 Tay KH, Lip GY, Lane DA. Atrial fibrillation and stroke risk prevention in real-life clinical practice. Thromb Haemost 2009; 101: 415-416.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Aspinall SL, Zhao X, Handler SM. et al. The quality of warfarin prescribing and monitoring in Veterans Affairs nursing homes. J Am Geriatr Soc 2010; 58: 1475-1480.
    CrossrefPubMedGoogle Scholar
  • 17 Lip GY, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
    CrossrefPubMedGoogle Scholar
  • 18 Wieloch M, Själander A, Frykman V. et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J. 2011. epub ahead of print
    Google Scholar
  • 19 Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010; 104: 1099-1105.
    Article in Thieme ConnectPubMedGoogle Scholar